Apellis Pharmaceuticals Inc (APLS)
27.51
-0.55
(-1.96%)
USD |
NASDAQ |
Oct 04, 16:00
27.60
+0.09
(+0.33%)
After-Hours: 20:00
Apellis Pharmaceuticals Shareholders Equity (Annual): 194.52M for Dec. 31, 2023
Shareholders Equity (Annual) Chart
Historical Shareholders Equity (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 194.52M |
| December 31, 2022 | 169.87M |
| December 31, 2021 | 198.66M |
| December 31, 2020 | 204.56M |
| December 31, 2019 | 34.23M |
| December 31, 2018 | 160.97M |
| Date | Value |
|---|---|
| December 31, 2017 | 148.94M |
| December 31, 2016 | 23.79M |
| December 31, 2015 | 34.98M |
| December 31, 2014 | 13.22M |
| December 31, 2013 | 4.522M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Annual) Range, Past 5 Years
34.23M
Minimum
2019
204.56M
Maximum
2020
160.37M
Average
194.52M
Median
2023
Shareholders Equity (Annual) Benchmarks
| EyePoint Pharmaceuticals Inc | 266.32M |
| Cassava Sciences Inc | 137.47M |
| Adverum Biotechnologies Inc | 83.47M |
| Rocket Pharmaceuticals Inc | 492.57M |
| Regenxbio Inc | 311.74M |